RA Capital Management Overview
- Investor Type
- Hedge Fund
- Status
- Active
- Professionals
- 46
- Investments
- 297
- Portfolio
- 102
- Exits
- 161
RA Capital Management General Information
Description
Founded in 2001, RA Capital Management is a hedge fund manager based in Boston, Massachusetts. The firm focuses on evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices and diagnostics sectors.
Contact Information
Website
www.racap.com
Year Founded
2001
Investor Status
Actively Seeking New Investments
Primary Investor Type
Hedge Fund
Other Investor Types
Growth/Expansion
Venture Capital
Primary Office
- 200 Berkeley Street
- 18th Floor
- Boston, MA 02116
- United States
+1 (617) 000-0000
RA Capital Management Investments & Acquisitions (297)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Expansion Therapeutics | 29-Sep-2021 | Later Stage VC | 0000 | Drug Discovery | Generating Revenue | 000000 00000 00.0 |
| 00000 000000000000 | 27-Sep-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 00000 00.0 |
| 00000000 000000000 | 09-Sep-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 00000000 | 08-Sep-2021 | 00 000000000 | 00000 | Drug Discovery | Generating Revenue | |
| 0000000 | 08-Sep-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000 000000 00.0 |
| 00000 000000000000 | 01-Sep-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| 000 00000000000000 | 31-Aug-2021 | 00000 00000 | 0000 | Therapeutic Devices | Clinical Trials - General | 00000 0000000000 00.0 |
| 000000 00000000000 | 30-Aug-2021 | 00000 00000 | 000 | Drug Discovery | Generating Revenue | 000000 0000 |
| DiCE Molecules | 24-Aug-2021 | Later Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials | 0000 000000 00.0 |
| Jnana Therapeutics | 18-Aug-2021 | Early Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials | 0000000 0000000 00.0 |
RA Capital Management Exits (161)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Pyxis Oncology | 08-Oct-2021 | IPO | 00000 |
| 0000 000000000 | 15-Sep-2021 | 000 | 00000 |
| 0000 00000000000 | 15-Sep-2021 | 000 | 00000 |
| 00000 000000000000 | 10-Aug-2021 | 000 | 0000 |
| 000000 00000000000 | 06-Aug-2021 | 000 | 00000 |
| 0000000 | 30-Jul-2021 | 000 | 00000 |
| 000000 00000000000 | 30-Jul-2021 | 000 | 00000 |
| 00000000 | 29-Jul-2021 | 000 | 00000 |
| Cytek | 23-Jul-2021 | IPO | 00000 |
| TScan Therapeutics | 16-Jul-2021 | IPO | 00000 |
RA Capital Management Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialRA Capital Management Team (93)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Kai Wu | Chief Financial Officer | Boston, MA | |||
| Michael Saulnier | Chief Financial Officer | Boston, MA | |||
| Andrew Levin Ph.D | Managing Director | 00 | 0 | 0 | Boston, MA |
| Pieter Boelhouwer JD | Managing Director, Strategy and Operations | 0 | Boston, MA | ||
| Peter Kolchinsky Ph.D | Founder & Managing Partner | 00 | 0 | 00 | Boston, MA |
RA Capital Management Co-Investors (461)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Janus Henderson Investors | 29 | 0 | 0 |
|
|
| Cormorant Asset Management | 00 | 0 | 0 |
|
|
| Logos Capital | 00 | 0 |
|
|
|
| OrbiMed | 00 | 0 | 00 |
|
|
| Perceptive Advisors | 00 | 0 | 00 |
|
|